tirzepatide and nafld Madrigal, Novo Nordisk, Eli Lilly Comparison Nonalcoholic fatty liver disease: Current

3d and Table 1)

These findings should therefore be interpreted cautiously and seen as hypothesis-generating

Prior research has confirmed the effect of semaglutide in managing blood sugar, decreasing cardiovascular disease events and reducing weight in people with Type 2 diabetes, this study specifically investigated the potential impact of semaglutide on cardiovascular disease in people with overweight or obesity and cardiovascular disease who did not have either Type 1 or Type 2 diabetes

Evidence has recently revealed that GLP-1RAs inhibit cardiac hypertrophy by upregulating GLP-1R expression and activating the AMPK/mechanistic target of the rapamycin (mTOR) signaling pathway [78]

However, there are notable differences in clinical oversight, frequency of live care, pricing transparency, and plan flexibility